FEMY News and Press, Femasys Inc. From 06/28/22

Buying Penny Stocks on June 28th? Here’s What You Need to Know Finding penny stocks that are worth buying can be challenging. And despite there being a lot of positive movement in the past few trading days, the overall characterization of the stock market right now is bearish. Th...

Gainers: Evofem Biosciences (EVFM) +172%. Acutus Medical (AFIB) +97%. NeuroSense (NRSN) +52%. Axsome (AXSM) +42%. Clene (CLNN) +35%. AeroClean (AERC) +28%. Femasys (FEMY) +30%. Scholar Rock Holding (SRRK) +22%. Precision Bio Sciences (DTIL) +20%. Boxed (BOXD) +19%. Losers: Powerbridge Technol...

Gainers: NeuroSense Therapeutics NRSN +83%. Axsome Therapeutics (AXSM) +37%. Agile Therapeutics (AGRX) +31%. GreenLight Biosciences (GRNA) +26%. Femasys (FEMY) +11%. Losers: GeoVax Labs GOVX -14%. SIGA Technologies (SIGA) -14%. Eargo (EAR) -12%. BioAtla...

Axsome Therapeutics (AXSM) +50%as FDA issues proposed labeling for depression drug. Agile Therapeutics (AGRX) +42%. Nutex Health (NUTX) +14%announces that it has been selected to join both the RUSSELL 2000® AND RUSSELL 3000® INDEXES. Femasys (FEMY) +16%. Siyata Mobile (SYTA) +1...

Gainers: USA Truck USAK +111%. ToughBuilt Industries TBLT +58%. Zendesk ZEN +29%. Femasys (FEMY) +30%. Chimerix CMRX +25%. Wrap Technologies (WRAP) +26%. Moving iMage Technologies MITQ +18%. TRACON Pharmaceuticals TCON +18%. LogicMark (LGMK) +16%. Zhong Yang Fina...

ATLANTA, June 15, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that President and...

Femasys press release (NASDAQ:FEMY): Q1 GAAP EPS of -$0.24. Revenue of $322.41M (-2.2% Y/Y) beats by $322.11M. For further details see: Femasys GAAP EPS of -$0.24, revenue of $322.41M beats by $322.11M

- Furthers advancement of much-needed minimally invasive technologies for underserved areas of women’s health with pending commercialization of products, FemCerv ® and FemCath ™ expected by year-end - Continued progress with FemaSeed and ...

ATLANTA, March 25, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company ...

Femasys press release (NASDAQ:FEMY): FY GAAP EPS of -$1.12. Revenue of $1.18M (+13.5% Y/Y). The cash and cash equivalents balance as of December 31, 2021 was $24.78M. For further details see: Femasys GAAP EPS of -$1.12, revenue of $1.18M